Victor Ho Fun Lee
Overview
Explore the profile of Victor Ho Fun Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
608
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun J, Lam S, Zhang J, Teng X, Lee F, Yip C, et al.
Radiol Med
. 2025 Jan;
130(3):381-396.
PMID: 39873917
Purpose: Bodyweight loss is commonly found in Nasopharyngeal Carcinoma patients during Concurrent Chemo-radiotherapy (CCRT) and has implications for treatment decisions. However, the prognostic value of this weight loss remains uncertain....
2.
Blechter B, Hsiung C, Wang X, Zhang H, Seow W, Shi J, et al.
J Thorac Oncol
. 2024 Nov;
PMID: 39581378
We assessed the association between a genome-wide polygenic risk score (PRS) developed for lung adenocarcinoma (LUAD) risk and mutation on the EGFR gene in 998 East Asian never-smoking female LUAD...
3.
Blechter B, Wang X, Shi J, Shiraishi K, Choi J, Matsuo K, et al.
medRxiv
. 2024 Jul;
PMID: 38978671
Polygenic risk scores (PRSs) are promising for risk stratification but have mainly been developed in European populations. This study developed single- and multi-ancestry PRSs for lung adenocarcinoma (LUAD) in East...
4.
Chiang C, Chan K, Li H, Ng W, Chow J, Choi H, et al.
Radiother Oncol
. 2024 Apr;
196:110287.
PMID: 38636709
Background: Locally advanced nasopharyngeal cancer (NPC) patients undergoing radiotherapy are at risk of treatment failure, particularly locoregional recurrence. To optimize the individual radiation dose, we hypothesize that the genomic adjusted...
5.
Kam N, Lo A, Hung D, Ko H, Wu K, Kwong D, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254759
The use of immune checkpoint inhibitors (ICIs) in cancer treatment has shown promise but can also have unintended consequences, such as reactivating latent tuberculosis (TB). To develop treatments that address...
6.
Kim J, Cheng J, Nam T, Kim J, Jang B, Huang W, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370774
Purpose: Although systemic treatment is the mainstay for advanced hepatocellular carcinoma (HCC), numerous studies have highlighted the added value of local treatment. This study aimed to investigate the clinical efficacy...
7.
Shi J, Shiraishi K, Choi J, Matsuo K, Chen T, Dai J, et al.
Nat Commun
. 2023 May;
14(1):3043.
PMID: 37236969
Lung adenocarcinoma is the most common type of lung cancer. Known risk variants explain only a small fraction of lung adenocarcinoma heritability. Here, we conducted a two-stage genome-wide association study...
8.
Chan J, Ng D, Liao Q, Fielding R, Soong I, Chan K, et al.
Sleep
. 2023 Mar;
46(8).
PMID: 36861253
Study Objectives: To examine the trajectories of sleep disturbance in cancer survivors during the first 2 years post-treatment and to investigate whether psychological, cognitive, and physical factors differentiate trajectories. Methods:...
9.
Kim N, Cheng J, Ohri N, Huang W, Kimura T, Zeng Z, et al.
J Hepatocell Carcinoma
. 2022 Aug;
9:707-715.
PMID: 35966184
Background/purpose: The Asian Liver Radiation Therapy Study Group has formed a large and detailed multinational database of outcomes following stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC). Here, we...
10.
So S, Ng D, Liao Q, Fielding R, Soong I, Chan K, et al.
Front Psychol
. 2022 May;
13:866346.
PMID: 35496253
Objectives: Working-age cancer patients face barriers to resuming work after treatment completion. Those resuming work contend with reduced productivity arising from persisting residual symptoms. Existing studies of return to work...